Menogaril: a new anthracycline agent entering clinical trials

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Menogaril (7(R)-O-methylnogarol, 7-OMEN) is a new anthracycline agent.
• Selected for clinical trials due to broad-spectrum murine antitumor activity and reduced cardiotoxicity compared to doxorubicin.

Purpose of the Study:

• To evaluate the antitumor potential, biochemical effects, and pharmacokinetic profile of menogaril.
• To compare menogaril's mechanism of action and toxicity with existing anthracyclines.

Main Methods:

• In vitro biochemical studies assessing DNA binding and RNA synthesis inhibition.
• Pharmacology studies in mice and dogs using HPLC for metabolite identification.
• Oral bioavailability and acute toxicity studies in rodents, dogs, and non-human primates.

Main Results:

• Menogaril exhibits weaker DNA binding and less RNA synthesis inhibition than doxorubicin.
• Demonstrates different cell cycle phase-specific cytotoxicity.
• Multiexponential plasma clearance and metabolism to N-demethylmenogaril and other metabolites observed.
• Significant oral absorption with first-pass metabolism in mice.
• Predominant toxicities in acute studies were myelosuppression and gastrointestinal issues.

Conclusions:

• Menogaril possesses distinct biochemical properties and pharmacokinetic behavior compared to other anthracyclines.
• Potential for oral administration and reduced cardiotoxicity are promising.
• Phase I clinical trials are ongoing to further assess safety and efficacy.